Investors Sell Johnson & Johnson (JNJ) on Strength (JNJ)

Traders sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading hours on Thursday. $126.17 million flowed into the stock on the tick-up and $327.20 million flowed out of the stock on the tick-down, for a money net flow of $201.03 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 0th highest net out-flow for the day. Johnson & Johnson traded up $0.83 for the day and closed at $140.82

A number of equities research analysts have recently issued reports on the company. Citigroup upped their price target on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Credit Suisse Group upped their price target on Johnson & Johnson from $149.00 to $152.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Raymond James upped their price target on Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a research report on Wednesday, October 17th. Wells Fargo & Co restated an “outperform” rating and issued a $160.00 price target (up from $155.00) on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Finally, HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $142.54.

The stock has a market capitalization of $377.43 billion, a price-to-earnings ratio of 17.70, a P/E/G ratio of 2.20 and a beta of 0.58. The company has a quick ratio of 1.33, a current ratio of 1.72 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the business posted $1.90 earnings per share. On average, analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date is Monday, November 26th. This represents a $3.60 annualized dividend and a yield of 2.56%. Johnson & Johnson’s payout ratio is 49.32%.

In related news, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares in the company, valued at $3,528,955.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

A number of institutional investors have recently modified their holdings of JNJ. PDS Planning Inc lifted its stake in Johnson & Johnson by 10.8% during the third quarter. PDS Planning Inc now owns 3,673 shares of the company’s stock worth $507,000 after purchasing an additional 357 shares in the last quarter. Trust Department MB Financial Bank N A raised its stake in shares of Johnson & Johnson by 0.4% in the third quarter. Trust Department MB Financial Bank N A now owns 98,938 shares of the company’s stock valued at $13,670,000 after acquiring an additional 363 shares in the last quarter. Global Retirement Partners LLC raised its stake in shares of Johnson & Johnson by 3.0% in the third quarter. Global Retirement Partners LLC now owns 12,394 shares of the company’s stock valued at $1,712,000 after acquiring an additional 365 shares in the last quarter. Canal Capital Management LLC raised its stake in shares of Johnson & Johnson by 2.3% in the third quarter. Canal Capital Management LLC now owns 16,077 shares of the company’s stock valued at $2,221,000 after acquiring an additional 365 shares in the last quarter. Finally, Cribstone Capital Management LLC raised its stake in shares of Johnson & Johnson by 1.2% in the third quarter. Cribstone Capital Management LLC now owns 32,102 shares of the company’s stock valued at $4,435,000 after acquiring an additional 376 shares in the last quarter. Institutional investors own 66.70% of the company’s stock.

Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Stop Order Uses For Individual Investors

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply